Cardiovascular diseases are the most common illnesses concomitant with depression. Approximately one in five patients with cardiovascular disease suffers from major depressive disorder (1). Depression should be considered to be a major risk factor for cardiovascular disease, specifically among elderly people. A previous study demonstrated that the associated risk of heart disease in patients with depression is ~1.6 times greater compared with individuals who do not suffer from depression (2). Furthermore, symptoms of depression are associated with an increased risk of myocardial infarction and stroke (3). Treatment of these concomitant diseases includes the prevention of heart diseases, and antidepressant therapies.

High blood cholesterol is associated with cardiovascular disease and is an important risk factor. The most effective and commonly used drugs to lower the levels of low-density lipoprotein lipids are statins; 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (4,5). Rosuvastatin induces the most potent reduction of LDL and elevation of high-density lipoprotein in its class of drug (6). Rosuvastatin effectively reduces the concentration of C-reactive protein by ~37%, and diminishes the risk of myocardial infarction, stroke and other cardiovascular events among individuals with established coronary heart disease (4,7). Severe adverse effects during this drug therapy are rare and include myopathy and rhabdomyolysis (8,9).

Among the available antidepressant agents, tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) are commonly chosen a first-line medications (10). TCAs are effective against depression but are associated with cardiovascular side-effects including orthostatic hypotension and slowed cardiac conduction (10). Amitriptyline is an effective TCA drug; however, it may cause anticholinergic side-effects (11). SSRIs are being increasingly used to treat depressed patients, including elderly individuals (10,12). SSRIs have comparable efficacy to TCAs against depression but are generally better tolerated (9). Fluoxetine is a commonly prescribed SSRI for patients with cardiac disease suffering from depression, as it does lead to the development of cardiovascular side-effects (13). The side-effects of fluoxetine are temporary and usually not life threatening, including gastrointestinal adverse effects (14). However, several clinical and animal studies have suggested that long-term therapy of fluoxetine induces hepatotoxicity (15,16).

Numerous studies on depression treatment in patients with cardiovascular diseases focused on the psychiatric consequences of medications and on the impact of antidepressant therapies on cardiovascular outcomes (9,12,17). Few investigations have been conducted on the influence of combined treatment with statins and antidepressant drugs on the function of internal organs (18,19). Both cardiovascular diseases and depression are chronic and require treatment with agents of different pharmacological profiles. When choosing treatment for depression in patients with cardiovascular disease, it should be noted that long-term simultaneous pharmacotherapy may lead to potential drug interactions, which may in turn disrupt the function of internal organs. All antidepressant agents are metabolized to some extent by the cytochrome P450 system and are associated with numerous pharmacokinetic drug interactions. Similarly, the majority of statins are hepatically biotransformed by cytochrome P450 action (20). Therefore, it is necessary to conduct preliminary studies on the impact of combined therapy with statins and antidepressants on the function of internal organs.

The present study investigated the influence of combined treatment with rosuvastatin and amitriptyline or fluoxetine for 14 days on the serum biochemical parameters indicating liver and kidney function in rats. In addition, the activity levels of aminotransferase (AST), alanine aminotransferase (ALT), and γ-glutamyltransferase (GGT) and the concentrations of total protein, urea, creatinine and β₂-microglobulin were assessed.

The results of the present study demonstrated that treatment with rosuvastatin alone increased the urea concentration compared with the control group. Although a high standard error of the mean value was observed, there were no effects on the other parameters to indicate renal function. Previous studies reported that rosuvastatin induces low levels of transient proteinuria (6,21). In short-term placebo-controlled trials, transient proteinuria was detected in 0.1% patients receiving rosuvastatin at a dose of 40 mg. Patient elevated proteinuria levels during rosuvastatin therapy were generally resolved spontaneously later during the trial (4,6,9). In addition, long-term data indicates that rosuvastatin appears to marginally improve renal function (6). Few studies have been conducted on kidney dysfunction during therapy with amitriptyline. The available data suggests that amitriptyline drug clearance is reduced in elderly people (12). Several studies have demonstrated the safety of fluoxetine in depressed patients with renal impairment (22,23). The results of the present study indicated that neither amitriptyline nor fluoxetine caused significant changes in the markers of renal function, including concentrations of total protein, urea, creatinine and β₂-microglobulin, as compared with the control group.

The data obtained from this study suggested that the administration of either rosuvastatin and amitriptyline or rosuvastatin and fluoxetine for 14 days did not significantly influence AST activity levels in the serum of rats. In addition, combined treatment with rosuvastatin and amitriptyline did not induce any significant changes in the activity levels of ALT, as compared with the rosuvastatin and amitriptyline alone groups. However, combined treatment with rosuvastatin and fluoxetine resulted in an increase in ALT activity levels in rat serum, as compared with rats treated with fluoxetine alone. Serum AST and ALT levels are the most useful indicators of liver cell injury, although AST is less liver-specific than ALT (24,25). It should be noted that an increase in ALT activity levels was associated with the group of rats receiving fluoxetine alone, whereas in the serum of the rats pretreated with fluoxetine a significant reduction in ALT activity was observed, as compared with the control group. Finally, the activity levels of this ALT in the rats treated with both rosuvastatin and fluoxetine was not significantly different compared with the control group. Our previous studies (18,19) demonstrated that combined treatment with simvastatin (10 mg/kg) and amitriptyline (10 mg/kg) for 14 days increased the activity levels of AST, whereas combined treatment with simvastatin (20 mg/kg) and doxepin (20 mg/kg) significantly increased the activity levels of both AST and ALT. This may be due to the fact that rosuvastatin is a poor substrate for metabolism by cytochrome P450, and it is less likely to cause metabolic drug-drug interactions. Furthermore, a study in which an increase in the activity levels of both AST and ALT were observed, drug concentrations twice as high were used (19). In the present study, combined treatment with rosuvastatin and amitriptyline in rats caused a significant increase in the activity levels of GGT compared with those treated with rosuvastatin alone. In addition, the combined administration of rosuvastatin and fluoxetine caused a significant increase in the activity levels of GGT compared with rosuvastatin or fluoxetine alone. GGT activity has been observed in numerous types of tissue, although it is considered as a serum marker primarily for the diagnosis of liver disease. Elevated serum GGT activity levels have been widely used as an early and sensitive marker of liver dysfunction (8). Therefore, the increased activity levels of the marked enzymes that were observed in the present study may suggest the possibility of liver function impairment during combined therapy with rosuvastatin and amitriptyline or fluoxetine. However, the administration of rosuvastatin for 14 days did not significantly influence the serum activity levels of the enzymes compared with the control group. Previous studies demonstrated that rosuvastatin may occasionally induce alterations in hepatic enzyme activity levels; however, these changes infrequently caused liver failure (4,6). In the controlled clinical trials of rosuvastatin, the incidence of clinically significant ALT increases was low, and similar across all doses (0.1–0.5%), and these elevations were dose-dependent (24,25). The results of the present study demonstrated that amitriptyline did not significantly affect the activity levels of the marker enzymes, compared with the control group. However, according to previous studies amitriptyline is an antidepressant drug associated with numerous adverse effects, including infrequent toxic liver injury (26). Furthermore, amitriptyline therapy may result in idiosyncratic hepatotoxicity, although this rarely occurs (27). Numerous studies have reported that fluoxetine induces liver damage, as demonstrated by elevated levels of aminotransferases, glutathione S-transferases, and acute hepatitis in humans and animals (15,16,28). However, in present study fluoxetine administered to the rats for 14 days lowered the activity levels of ALT compared with the control group.

The concentrations of total protein and β₂-microglobulin remained unaffected in the serum of the rats treated with rosuvastatin and amitriptyline or fluoxetine. Similarly, combined treatment with rosuvastatin and amitriptyline did not significantly influence urea concentration. However, rosuvastatin administered simultaneously with fluoxetine significantly increased the concentration of urea, as compared with the rats treated with fluoxetine alone. It should be noted that any significant changes observed in the serum of rats treated with rosuvastatin and fluoxetine were as compared with the control group. Additionally, any adverse effects of the simultaneous administration of rosuvastatin and fluoxetine on creatinine concentration were indicated. The results of the present investigation also demonstrated that combined treatment with rosuvastatin and amitriptyline for 14 days caused a significant increase in the concentration of creatinine, compared with rats treated with TCA alone. However, in the group of rats treated with rosuvastatin and amitriptyline, the high standard error of the mean was recorded and the concentration of creatinine was estimated to be within the limits of the control group. The alterations in serum markers observed in the present study do not clearly indicate an impaired renal function. The differences between combined treatment with rosuvastatin and amitriptyline or fluoxetine and the experimental marker activity levels and concentrations may be a result of the metabolism of these drugs. Rosuvastatin and fluoxetine are biotransformed in the liver by cytochrome P450 izoenzyme CYP2C9, although this izoenzyme is not involved in the metabolism of amitriptyline (4,29).

In conclusion, combined treatment with rosuvastatin and either antidepressant for 14 days increased the activity levels of GGT in the serum of rats compared with the control group, which suggested the impairment of liver function. Therefore, further long-term (28- and/or 90-day) animal model studies and prospective clinical analyses that specifically focus on the mechanisms underlying the adverse effects of combined treatment with statins and antidepressants on the liver and kidney functions, are required. However, according to the estimation of the marked biochemical parameters of renal function, it appears that the above-mentioned therapy does not adversely affect renal function in rats.